BridgeMD
A trial to determine the safety and effectiveness of CC-92480 in combination with bortezomib and dexamethasone as compared to pomalidomide in combination with bortezomib and dexamethasone in people who have Multiple Myeloma that is not responsive after treatment or has returned after a period of treatment.
EU CTIS ID: 2023-509859-13-00
What this study is testing
To compare the progression-free survival (PFS) of mezigdomide, bortezomib and dexamethasone (MeziVd) to that of pomalidomide, bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM)
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Subject has documented diagnosis of MM and measurable disease, defined as: —M-protein ≥ 0.5 g/dL by serum protein electrophoresis (sPEP), or ≥ 200 mg/24-hour urine collection by urine protein electrophoresis (uPEP) or —For subjects without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio
- Subject has received 1 to 3 prior anti-myeloma lines of therapy
- Subject must have received prior treatment with a lenalidomide containing regimen. For country-specific requirements, see APPENDIX I
- Subject achieved a minimal response [MR] or better to at least 1 prior antimyeloma therapy
- Subject must have documented disease progression during or after their last antimyeloma regimen
- Subject has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2.
You likely can't join if
- Subject has had prior treatment with mezigdomide or pomalidomide
- Subject has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor, except as noted below: a. Subjects who progressed while being treated with, or within 60 days of last dose of bortezomib maintenance given once every 2 weeks or less are not excluded.
- For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
The study team makes the final eligibility decision.
Where it's taking place
- Turkey
- Korea, Republic of
- Australia
- Brazil
- Argentina
- Japan
- United Kingdom
- Canada
- Israel
- United States
- China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Turkey; Korea, Republic of; Australia; Brazil; Argentina; Japan and 5 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.